A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension

Trial Profile

A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Ralinepag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 26 Jul 2017 This trial has been completed in Poland (End date 22-06-2017).
    • 25 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jul 2017 The trial has been completed in Czech Republic with end date 22-06-2017 according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top